Immuron Ltd ADR

Immuron Limited is an Australian biopharmaceutical company dual-listed on the ASX and NASDAQ, focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. The company's proprietary platform technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum, which can withstand stomach acid and digestive enzymes to remain active in the gastrointestinal tract. Immuron's commercial product, Travelan, is an oral passive immunotherapy that reduces the likelihood of travelers' diarrhea caused by pathogenic bacteria and is sold in Australia (as a listed therapeutic), Canada (as a licensed natural health product), and the United States (as a dietary supplement). The company also distributes ProIBS, a certified medical device for treating irritable bowel syndrome symptoms, under an exclusive agreement for Australia, New Zealand, and (as of September 2026) the United States. Immuron's clinical pipeline includes IMM-124E (the drug form of Travelan, eligible for end-of-Phase 2 FDA meeting) and IMM-529, a first-in-class triple-action biologic targeting Clostridioides difficile infection that has FDA IND approval and is ready for Phase 2 trials. The company has adopted a partnering strategy for its clinical assets, seeking licensees to fund further development and commercialization while focusing internally on growing its over-the-counter product portfolio and achieving profitability. Updated Sep 22, 2026